Saunders, Kevin O
- Duke University · Surgery (NIH department code)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #609
- Top 5% Funded
- R01 Holder
- Long-Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2009 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2023 award categories
- Surgery
NIH Funding · FY2023
Linked Award Amount
$5.6M
Full award amounts, FY2023
Award Records
2
Records listing this PI
Award-Linked Rank
#609
By linked amount among FY2023 PIs
Earliest Year Loaded
2009
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Saunders, Kevin O as a PI. Multi-PI records show the full award amount for context.
- 5U19AI160546-02U19Contact PIConjugate nanoparticle platform development for HIV-1 envelope immunogensDuke University · Surgery (NIH department code)$4.8Maward amount
- 5R01AI120801-09R01Contact PIHIV-1 vaccine-elicited antibodies target envelope glycansDuke University · Surgery (NIH department code)$747.5Kaward amount
Award organization
Organizations that administered FY2023 awards listing Saunders, Kevin O as a PI.
FY2023 award administered by Duke University (NC).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2009First NIH AwardDuke University
- 2015$500K Cumulative Funding
- 2015Entered Top 50% NationallyRanked #9520
- 2016$1M Cumulative Funding
- 2016R01 Grant Holder
- 2017$2M Cumulative Funding
- 2022$5M Cumulative Funding
- 2022Entered Top 25% NationallyRanked #622
- 2022Entered Top 10% NationallyRanked #622
- 2022Entered Top 5% NationallyRanked #622
- 2023$10M Cumulative Funding